<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27882" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Protein S Deficiency</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Ashish</given-names>
          </name>
          <aff>Internal Medicine, The Brooklyn Hospital Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tun</surname>
            <given-names>Aung M.</given-names>
          </name>
          <aff>Division of Hematology, Mayo Clinic, Rochester, MN</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Kush</given-names>
          </name>
          <aff>Kasturba Medical College, Mangalore</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Tuma</surname>
            <given-names>Faiz</given-names>
          </name>
          <aff>Central Michigan University</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Ashish Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Aung Tun declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kush Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Faiz Tuma declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>5</day>
          <month>12</month>
          <year>2022</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27882.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Protein S deficiency is a rare disorder characterized by reduced activity of protein S, a plasma serine protease with complex roles in coagulation, inflammation, and apoptosis. Protein S is an anticoagulant protein discovered in Seattle, WA, in 1979 (hence the name); it&#x000a0;facilitates the action of activated protein C (APC) on activated factor 5 (F5a) and activated factor 8 (F8a). A deficiency in protein S characteristically demonstrates the inability to control coagulation, resulting in the excessive formation of blood clots (thrombophilia) and venous thromboembolism (VTE). This activity reviews the presentation, evaluation, and management of protein S deficiency and highlights the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify&#x000a0;the etiology of protein S deficiency.</p></list-item><list-item><p>Evaluate&#x000a0;protein S deficiency.</p></list-item><list-item><p>Determine how to manage a patient with protein S deficiency.</p></list-item><list-item><p>Communicate&#x000a0;the importance of improving care coordination among the interprofessional team to enhance care delivery for patients with protein S deficiency.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27882&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27882">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27882.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Protein S deficiency is a rare disorder characterized by reduced activity of protein S, a plasma serine protease with complex roles in coagulation, inflammation, and apoptosis.<xref ref-type="bibr" rid="article-27882.r1">[1]</xref> Protein S is an anticoagulant protein discovered in Seattle, Washington, in 1979&#x000a0;(hence the name); it&#x000a0;facilitates the action of activated protein C (APC) on activated factor 5 (F5a) and activated factor 8 (F8a).&#x000a0;A deficiency in protein S characteristically demonstrates the inability to control coagulation, resulting in the excessive formation of blood clots (thrombophilia) and venous thromboembolism (VTE).<xref ref-type="bibr" rid="article-27882.r2">[2]</xref>&#x000a0;Protein S deficiency can be hereditary or acquired. The acquired deficiency is usually due to hepatic disease, nephrotic syndrome, or vitamin K deficiency. Hereditary protein S deficiency is an autosomal dominant trait. Thrombosis is observed in both heterozygous and homozygous genetic deficiencies of protein S.</p>
        <p>Protein S deficiency usually manifests as VTE and any association between protein S deficiency and arterial thrombosis appears coincidental or weak. There is minimal evidence for arterial thrombosis in other forms of hereditary thrombophilias, such as protein C deficiency, antithrombin 3 deficiency, or factor V Leiden.<xref ref-type="bibr" rid="article-27882.r3">[3]</xref></p>
      </sec>
      <sec id="article-27882.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Protein S deficiency can be congenital or acquired. Mutations in the <italic toggle="yes">PROS1</italic> gene cause congenital protein S deficiency.<xref ref-type="bibr" rid="article-27882.r4">[4]</xref>&#x000a0;Most <italic toggle="yes">PROS</italic>&#x000a0;mutations are point mutations, such as transversion mutations, that produce a premature stop codon and thus result in a truncated protein S molecule.<xref ref-type="bibr" rid="article-27882.r5">[5]</xref><xref ref-type="bibr" rid="article-27882.r6">[6]</xref>&#x000a0;More than 200 <italic toggle="yes">PROS</italic> mutations have been described and may result in&#x000a0;3 different forms of protein S deficiency:</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Type 1:</bold>&#x000a0;Quantitative defect presenting with low levels of total protein S (TPS) and free protein S (FPS), with reduced levels of protein S activity</p>
          </list-item>
          <list-item>
            <p><bold>Type 2 (also known as type 2b):</bold> Decreased protein S activity, with normal levels of TPS and FPS antigens</p>
          </list-item>
          <list-item>
            <p><bold>Type 3 (also known as Type 2a):</bold>&#x000a0;Quantitative defect presenting with normal levels of TPS but reduced levels of FPS and protein S activity</p>
          </list-item>
        </list>
        <p>Protein S deficiency is an autosomal dominant pathology. Mutations in a single copy in heterozygous individuals cause mild protein S deficiency, whereas individuals with homozygous mutations present with severe protein S deficiency.</p>
        <p>Causes of acquired fluctuations in protein S levels may include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Vitamin K-antagonist therapy</p>
          </list-item>
          <list-item>
            <p>Chronic infections</p>
          </list-item>
          <list-item>
            <p>Severe hepatic disease</p>
          </list-item>
          <list-item>
            <p>Systemic lupus erythematosus</p>
          </list-item>
          <list-item>
            <p>Myeloproliferative disorders</p>
          </list-item>
          <list-item>
            <p>Nephritic syndrome</p>
          </list-item>
          <list-item>
            <p>Disseminated intravascular coagulation (DIC)&#x000a0;<xref ref-type="bibr" rid="article-27882.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>The risk of VTE is also increased in patients using oral contraceptives and pregnancy&#x000a0;<xref ref-type="bibr" rid="article-27882.r8">[8]</xref><xref ref-type="bibr" rid="article-27882.r9">[9]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27882.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Congenital protein S deficiency is autosomal dominant, with variable penetrance. 50% of patients who are heterozygous for protein S deficiency develop VTE; the remaining 50% are asymptomatic and never develop VTE. The annual incidence of venous thrombosis is 1.90%, with 29 years being the median age of presentation. Protein S deficiency can occur as a homozygous state, and these individuals develop purpura fulminans. Purpura fulminans appear during the neonatal period and are characterized by small-vessel thrombosis with cutaneous and subcutaneous necrosis. Estimates of mild congenital protein S deficiency incidence are between 1 in 500 individuals. Severe&#x000a0;protein S deficiency&#x000a0;is rare, and its prevalence in the general population remains unknown due to difficulty diagnosing the condition.</p>
        <p>Protein S deficiency rarely occurs in healthy people without VTE. In a study on healthy blood donors, the prevalence of the familial form of protein S deficiency was found to be 0.03 to 0.13%.<xref ref-type="bibr" rid="article-27882.r10">[10]</xref>&#x000a0;When a select group of patients with a history of recurrent thrombosis or a family history significant for thrombosis is assessed, the frequency of protein S deficiency&#x000a0;rises to between 3&#x000a0;and 5%.<xref ref-type="bibr" rid="article-27882.r11">[11]</xref><xref ref-type="bibr" rid="article-27882.r12">[12]</xref></p>
        <p>Studies reporting on the clinical significance of the association between protein S levels and VTE risk suggest lowering the cutoff of protein S levels required for the diagnosis. This would, in turn, change the prevalence of the disease.<xref ref-type="bibr" rid="article-27882.r13">[13]</xref>&#x000a0;Data from the US and European studies reveal no difference in the prevalence of protein S deficiency. However, protein S deficiency is higher in the Japanese population, at 12.7% in patients with VTE and around 0.48% to 0.63% in the general population.<xref ref-type="bibr" rid="article-27882.r14">[14]</xref></p>
        <p>Protein S deficiency is rare in the healthy population. In a study of 3788 persons, the prevalence of familial protein S deficiency was 0.03 to 0.13%.<xref ref-type="bibr" rid="article-27882.r10">[10]</xref>&#x000a0;In&#x000a0;patients with a family history of thrombosis or recurrent thrombosis, the frequency of protein S deficiency increases to 3% to 5%.</p>
        <p>
<bold>Race</bold>
</p>
        <p>Protein S deficiency is 5&#x000a0;to 10 times more common in Japanese populations than in whites. The prevalence of protein S deficiency is 0.48%&#x000a0;to 0.63% in the general Japanese population&#x000a0;and 12.7% in patients with thrombosis.</p>
        <p>
<bold>Sex</bold>
</p>
        <p>Men have a higher level of protein S antigen.</p>
        <p>
<bold>Age</bold>
</p>
        <p>The age of onset of thrombosis varies by heterozygous versus homozygous state. Heterozygous protein S deficiency causes thrombosis in persons younger than 40&#x000a0;to 45. The rare homozygous patients have onset in early infancy.</p>
      </sec>
      <sec id="article-27882.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Protein S is a vitamin K-dependent protease that circulates in plasma at low concentrations and serves a crucial role in the regulation of coagulation. In normal circumstances, the anticoagulant proteins keep the blood in a liquid, non-thrombotic state. In circulation, approximately 40% of protein S is free, and about 60% is in a high-affinity complex with the complement regulatory factor C4b-binding protein (C4BP).<xref ref-type="bibr" rid="article-27882.r4">[4]</xref> The anticoagulant activity of protein S is expressed in&#x000a0;2 ways:</p>
        <list list-type="order">
          <list-item>
            <p>Protein S is a cofactor for activated protein C (APC) and inactivating coagulation factors 5a and 8a. This process is designed to stop clotting by switching off the cofactor proteins F5a and F8a. Protein S and APC can inactivate FVa. However, for the inactivation of factor 8a, APC and protein S need factor 5.</p>
          </list-item>
          <list-item>
            <p>Protein S is also a cofactor for the tissue factor pathway inhibitor (TFPI) protein, resulting in the inactivation of factor 10a and tissue factor (TF)/factor 7a.<xref ref-type="bibr" rid="article-27882.r1">[1]</xref><xref ref-type="bibr" rid="article-27882.r15">[15]</xref><xref ref-type="bibr" rid="article-27882.r16">[16]</xref></p>
          </list-item>
        </list>
        <p>Protein S is a complex protein with multiple structural moieties. Protein S is a single-chain glycoprotein, and it is dependent on vitamin K action for posttranslational modification of the protein to a normal functional state. The 3-dimensional structure is yet to be resolved but is expected to contribute to understanding the complex functional nature of <italic toggle="yes">PROS1</italic> mutations.</p>
      </sec>
      <sec id="article-27882.s6" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>
<bold>History</bold>
</p>
        <p>The symptoms in patients with heterozygous protein S deficiency and mild reductions in protein S activity can range in severity. Almost half of all individuals with protein S deficiency become symptomatic before age 55.<xref ref-type="bibr" rid="article-27882.r17">[17]</xref> Venous thrombotic events (VTE), including parenchymal thrombi, deep vein thrombosis (DVT), pulmonary emboli (PE), and a propensity to DIC are common clinical manifestations,&#x000a0;with some patients also experiencing cerebral, visceral, or axillary vein thrombosis.<xref ref-type="bibr" rid="article-27882.r18">[18]</xref> Some women may have fetal loss as their only manifestation of protein S deficiency. Approximately half of these recurrent VTE episodes occur in the absence of common risk factors for thrombosis. The variability in risk of thrombotic events in carriers of protein S mutations may be due to different functional consequences of <italic toggle="yes">PROS1</italic> mutations, incomplete gene penetrance, exposure to thrombotic risk factors, and environmental or other genetic influences.<xref ref-type="bibr" rid="article-27882.r19">[19]</xref>&#x000a0;A family history of thrombosis suggests inherited thrombophilia.&#x000a0;Thrombosis before the age of 55 or recurrent thrombosis indicates an inherited thrombophilic state like protein S deficiency.</p>
        <p>Severe protein S deficiency resulting from congenital homozygous mutations presents in neonates soon after birth and has a characteristic presentation of purpura fulminans (PF). Affected individuals rarely survive childhood without early diagnosis and treatment.</p>
        <p>
<bold>Physical</bold>
</p>
        <p>The results of the physical examination are generally nonspecific and often misleadingly lead to the diagnosis of DVT. Uncommon sites of thrombosis, such as a mesenteric vein, cerebral sinuses, etc., are rare.<xref ref-type="bibr" rid="article-27882.r20">[20]</xref></p>
        <p>
<bold>Deep Vein Thrombosis</bold>
</p>
        <p>Venous thrombosis is the most common presentation in almost 90% of cases. The classic presentation of DVT includes calf pain, edema, and pain on dorsiflexion of the foot (i.e., Homan sign). All these&#x000a0;3 findings are present in less than a third of DVT cases. The most common finding is unilateral leg or calf swelling with mild or moderate pain. Superficial thrombophlebitis can also be seen in some cases, with or without DVT.</p>
        <p>
<bold>Pulmonary Embolism</bold>
</p>
        <p>Patients with pulmonary embolism present with dyspnea, chest pain, syncope, and palpitations. Tachypnea is the most frequent sign. Massive pulmonary embolism can present with syncope or cyanosis. Massive embolism also presents with acute right-sided heart failure. Patients have distended neck veins, a left parasternal lift, and an accentuated pulmonic component of the second heart sound.</p>
      </sec>
      <sec id="article-27882.s7" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Diagnostic testing for protein S deficiency is performed using functional assays, including clotting assays and enzyme-linked immunosorbent assays (ELISA), to determine levels of protein S activity.<xref ref-type="bibr" rid="article-27882.r21">[21]</xref></p>
        <p>
<bold>Protein S Antigen</bold>
</p>
        <p>Protein S antigen can be detected as total antigen or free protein S antigen. The free form of protein S is functionally active. Both free and total protein S can be measured by ELISA.</p>
        <p>
<bold>Functional Protein S</bold>
</p>
        <p>Functional protein S assays are indirect and based on the prolongation of blood clotting by forming activated protein C (APC) and its function in the assay.</p>
        <p>Many conditions reduce the blood levels of protein S on both antigenic and functional assays. These include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Vitamin K deficiency</p>
          </list-item>
          <list-item>
            <p>Liver disease</p>
          </list-item>
          <list-item>
            <p>Antagonism with warfarin reduces protein S levels</p>
          </list-item>
          <list-item>
            <p>Acute thrombosis</p>
          </list-item>
          <list-item>
            <p>Pregnancy</p>
          </list-item>
        </list>
        <p>Plasma protein S levels fluctuate with age, gender, and genetic or acquired influences such as hormonal status or lipid metabolism.<xref ref-type="bibr" rid="article-27882.r22">[22]</xref> Total and free protein S levels are lower in women than in men, although total protein S levels increase with age, and this is more pronounced in women due to deviations in hormone levels.&#x000a0;Free protein S levels are not affected by age.&#x000a0;Most importantly, a falsely low functional protein S can be seen in patients with factor V Leiden, a disorder that interferes with protein C function. There are some new commercial methods available for determining protein S deficiency in factor V Leiden accurately after dilution of test plasma.<xref ref-type="bibr" rid="article-27882.r23">[23]</xref><xref ref-type="bibr" rid="article-27882.r24">[24]</xref></p>
        <p>Protein S deficiency is classified into 3 phenotypes based on free and total protein S antigen and functional protein S activity by the International Society on Thrombosis and Hemostasis (ISTH), as discussed in the etiology section. Type 2 deficiency is rare. The most common are types 1 and 3.</p>
        <p>Total protein S tests perform excellently but cannot detect type 2 and 3 protein S deficiency. Free protein S assays may be a useful alternative, although they lack reproducibility. Measurement of APC cofactor activity could be used as a proxy indicator of protein S deficiency, although these assays have a high false-positive rate.</p>
        <p>Mutational analysis of the <italic toggle="yes">PROS1</italic> gene can be important in diagnosing protein S deficiency, and ISTH maintains a registry of documented mutations.</p>
        <p>Hemostasis analysis (per ISTH): Diagnosis of <italic toggle="yes">PROS1</italic> mutations is performed using DNA sequencing or amplification and analysis by polymerase chain reaction (PCR) followed by gel electrophoresis.</p>
      </sec>
      <sec id="article-27882.s8" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Protein S deficiency is managed in case of acute venous thromboembolism (VTE). In asymptomatic carriers without thrombotic events, prophylaxis may be used. Management of acute thrombosis is the same as for all acute VTE episodes, based on disease severity and hemodynamic stability. VTE management is by the administration of anticoagulation therapies such as heparin (low-molecular-weight heparin or unfractionated), vitamin K antagonist (VKA), or direct oral anticoagulant (DOAC). Initial heparin treatment may be with intravenous unfractionated heparin or subcutaneous low molecular weight heparin (LMWH). Heparin should be given for a minimum of&#x000a0;5 days, followed by&#x000a0;vitamin K antagonist (VKA) or direct oral anticoagulant (DOAC). The choice between a DOAC and VKA depends on patient preference and convenience. In the past, VKA was the drug of choice for VTE, but it has changed with the advent of DOACs. Due to their efficacy and safety profile, DOACs are now increasingly used for VTE.&#x000a0;In a cohort study of patients with inherited thrombophilias, DOACs had the same efficacy as heparin/VKAs, but there was an increased risk of non-major bleeding, while VKAs had a slightly increased risk of significant bleeding.<xref ref-type="bibr" rid="article-27882.r25">[25]</xref></p>
        <p>Patients with congenital protein S deficiency normally receive anticoagulation therapy for a longer duration until coagulation activity has stabilized for at least&#x000a0;2 consecutive days.<xref ref-type="bibr" rid="article-27882.r18">[18]</xref> Prophylactic anticoagulation therapy with warfarin is sustained for 3 to 6 months following a thrombotic episode and should be for longer durations in patients with coexisting coagulation conditions.<xref ref-type="bibr" rid="article-27882.r18">[18]</xref>&#x000a0;Lifelong therapy is recommended if the first thrombotic event is life-threatening or occurs in multiple or unusual sites (eg, cerebral veins, mesenteric veins). Lifelong anticoagulation is not recommended if the thrombotic event is precipitated by a strong event (trauma, surgery) and the thrombosis is not life-threatening or involves multiple or unusual sites.</p>
        <p>Prophylactic treatment should also be administered to patients with protein S deficiency exposed to thrombotic risk factors such as air travel, surgery, pregnancy, or long periods of immobilization. During pregnancy, patients in the first trimester or after 36 weeks should be treated with low-molecular-weight heparin rather than warfarin to reduce the risk of fetal and maternal bleeding.<xref ref-type="bibr" rid="article-27882.r18">[18]</xref><xref ref-type="bibr" rid="article-27882.r26">[26]</xref></p>
      </sec>
      <sec id="article-27882.s9" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Patients with thrombophilia without other risk factors may suffer from protein S deficiency. Alternative causes of thrombophilia include other congenital coagulation abnormalities or a combination of protein S deficiency with other VTE risk factors. Protein S deficiency may also be an acquired condition rather than congenital due to conditions including pregnancy, vitamin K deficiency, oral contraceptives, severe hepatic dysfunction, and chronic infections. Differential diagnoses that must be considered in patients with protein S deficiency include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Antiphospholipid syndrome</p>
          </list-item>
          <list-item>
            <p>Antithrombin deficiency</p>
          </list-item>
          <list-item>
            <p>Factor 5 Leiden mutation</p>
          </list-item>
          <list-item>
            <p>Protein C deficiency</p>
          </list-item>
          <list-item>
            <p>Malignancy</p>
          </list-item>
          <list-item>
            <p>Prothrombin gene mutation</p>
          </list-item>
          <list-item>
            <p>Paroxysmal nocturnal hemoglobinuria&#x000a0;<xref ref-type="bibr" rid="article-27882.r27">[27]</xref><xref ref-type="bibr" rid="article-27882.r28">[28]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27882.s10" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>Patients with mild protein S deficiency are prone to recurrent episodes of VTEs, including DVT. VTE induces significant morbidity and mortality. However, little evidence suggests that thrombophilia related to protein S deficiency results in a deteriorated prognosis for VTE. The development of recurrent thrombotic events in individuals with thrombophilia can contribute to increased morbidity. Furthermore, extended periods of anticoagulation treatment with warfarin can lead to an increased risk of bleeding.</p>
        <p>Neonates presenting with severe protein S deficiency have a poor prognosis. Complications from frequent infusions of plasma, such as fluid overload, contribute to a high infant death rate. There is limited data regarding the long-term outcome of patients with severe congenital protein S deficiency.</p>
      </sec>
      <sec id="article-27882.s11" sec-type="Complications">
        <title>Complications</title>
        <p>Complications of protein S deficiency are categorized into&#x000a0;2 groups, ie, complications due to protein S deficiency and complications due to the anticoagulation therapy.</p>
        <p>
<bold>Complications of Protein S Deficiency</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Post-thrombotic phlebitis</p>
          </list-item>
          <list-item>
            <p>Recurrent pulmonary embolism can cause cor pulmonale</p>
          </list-item>
          <list-item>
            <p>Early fetal loss</p>
          </list-item>
          <list-item>
            <p>Purpura Fulminas</p>
          </list-item>
        </list>
        <p>
<bold>Complications of Anticoagulation</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In adolescents and adults, long-term anticoagulation therapy increases the cumulative likelihood of severe bleeding complications.</p>
          </list-item>
          <list-item>
            <p>Skin necrosis is a complication associated with warfarin treatment and is manageable with short-term heparin administration.<xref ref-type="bibr" rid="article-27882.r18">[18]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27882.s12" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>At home, patient monitoring using point-of-care testing for fluctuations in international normalized ratios (INR) has eased the care of individuals with protein S deficiency. When combined with short-term anticoagulation therapy, proactive, patient-directed management can prevent recurrent episodes of thrombotic events requiring hospitalization. The use of compression stockings can also aid in preventing VTE events.</p>
      </sec>
      <sec id="article-27882.s13" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Protein S deficiency is a rare pathology that can be acquired or congenital. The most significant morbidity is that it predisposes patients to blood clots in the legs, brain, intestine, and lungs. The condition can also lead to premature birth and other complications during pregnancy. Because of its varied presentation, the disorder is best managed by an interprofessional team that includes clinicians, specialists, nurses, and pharmacists.</p>
        <p>These patients are initially managed by a hematologist and followed up by the primary care provider or nurse practitioner. All healthcare workers participating in the care of these patients should refer to published guidelines and recommendations developed by organizations such as the American Society of Hematology for guidance in treating and managing children with coagulation abnormalities.<xref ref-type="bibr" rid="article-27882.r29">[29]</xref></p>
        <p>Since many patients present with a first-time thrombotic event, the key is to have a suspicion of the disorder to make the diagnosis. Once diagnosed, the pharmacist should educate the patient on anticoagulation compliance; otherwise, there is a risk of devastating thrombotic complications.</p>
        <p>Because deep vein thrombosis can lead to post-thrombotic phlebitis, the nurse and pharmacist should coordinate the patient's education on the importance of wearing compression stockings.</p>
        <p>Additionally, the interprofessional team should regularly monitor the levels of prothrombin time and INR in patients managed with warfarin. Any deviation from therapeutic levels should be communicated to the hematologist, who should be the only one in charge of changing the dose and frequency. An internist should have input for those on oral anticoagulation who need elective surgery because these patients may require bridge therapy with heparin. Females of childbearing age who want to get pregnant should consult a hematologist first and be closely followed by a hematology nurse practitioner if they decide to conceive. Only with an interprofessional team approach can the morbidity of protein S deficiency be reduced and outcomes improved.&#x000a0;</p>
      </sec>
      <sec id="article-27882.s14">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27882&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27882">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/blood-disorders/protein-s-deficiency/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=27882">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27882/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27882">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27882.s15">
        <title>References</title>
        <ref id="article-27882.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dahlb&#x000e4;ck</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Vitamin K-Dependent Protein S: Beyond the Protein C Pathway.</article-title>
            <source>Semin Thromb Hemost</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>44</volume>
            <issue>2</issue>
            <fpage>176</fpage>
            <page-range>176-184</page-range>
            <pub-id pub-id-type="pmid">28905350</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r2">
          <label>2</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Gupta</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tun</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Tuma</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <chapter-title>Protein S Deficiency</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2022</year>
            <month>12</month>
            <day>5</day>
            <pub-id pub-id-type="pmid">31335064</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soare</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Popa</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Deficiencies of proteins C, S and antithrombin and activated protein C resistance--their involvement in the occurrence of Arterial thromboses.</article-title>
            <source>J Med Life</source>
            <year>2010</year>
            <season>Oct-Dec</season>
            <volume>3</volume>
            <issue>4</issue>
            <fpage>412</fpage>
            <page-range>412-5</page-range>
            <pub-id pub-id-type="pmid">21254740</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Castoldi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hackeng</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Regulation of coagulation by protein S.</article-title>
            <source>Curr Opin Hematol</source>
            <year>2008</year>
            <month>Sep</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>529</fpage>
            <page-range>529-36</page-range>
            <pub-id pub-id-type="pmid">18695379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jang</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HJ</given-names>
              </name>
            </person-group>
            <article-title>A novel nonsense mutation Tyr301* of PROS1 causing protein S deficiency.</article-title>
            <source>Blood Coagul Fibrinolysis</source>
            <year>2015</year>
            <month>Mar</month>
            <volume>26</volume>
            <issue>2</issue>
            <fpage>223</fpage>
            <page-range>223-4</page-range>
            <pub-id pub-id-type="pmid">25255242</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Huang</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Assa</surname>
                <given-names>CR</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
            </person-group>
            <article-title>Recurrent pulmonary embolism associated with deep venous thrombosis diagnosed as protein s deficiency owing to a novel mutation in PROS1: A case report.</article-title>
            <source>Medicine (Baltimore)</source>
            <year>2018</year>
            <month>May</month>
            <volume>97</volume>
            <issue>19</issue>
            <fpage>e0714</fpage>
            <pub-id pub-id-type="pmid">29742732</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rezende</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Simmonds</surname>
                <given-names>RE</given-names>
              </name>
              <name>
                <surname>Lane</surname>
                <given-names>DA</given-names>
              </name>
            </person-group>
            <article-title>Coagulation, inflammation, and apoptosis: different roles for protein S and the protein S-C4b binding protein complex.</article-title>
            <source>Blood</source>
            <year>2004</year>
            <month>Feb</month>
            <day>15</day>
            <volume>103</volume>
            <issue>4</issue>
            <fpage>1192</fpage>
            <page-range>1192-201</page-range>
            <pub-id pub-id-type="pmid">12907438</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>van Vlijmen</surname>
                <given-names>EF</given-names>
              </name>
              <name>
                <surname>Brouwer</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Veeger</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Eskes</surname>
                <given-names>TK</given-names>
              </name>
              <name>
                <surname>de Graeff</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>van der Meer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Oral contraceptives and the absolute risk of venous thromboembolism in women with single or multiple thrombophilic defects: results from a retrospective family cohort study.</article-title>
            <source>Arch Intern Med</source>
            <year>2007</year>
            <month>Feb</month>
            <day>12</day>
            <volume>167</volume>
            <issue>3</issue>
            <fpage>282</fpage>
            <page-range>282-9</page-range>
            <pub-id pub-id-type="pmid">17296885</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Seligsohn</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Lubetsky</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Genetic susceptibility to venous thrombosis.</article-title>
            <source>N Engl J Med</source>
            <year>2001</year>
            <month>Apr</month>
            <day>19</day>
            <volume>344</volume>
            <issue>16</issue>
            <fpage>1222</fpage>
            <page-range>1222-31</page-range>
            <pub-id pub-id-type="pmid">11309638</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dykes</surname>
                <given-names>AC</given-names>
              </name>
              <name>
                <surname>Walker</surname>
                <given-names>ID</given-names>
              </name>
              <name>
                <surname>McMahon</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Islam</surname>
                <given-names>SI</given-names>
              </name>
              <name>
                <surname>Tait</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>A study of Protein S antigen levels in 3788 healthy volunteers: influence of age, sex and hormone use, and estimate for prevalence of deficiency state.</article-title>
            <source>Br J Haematol</source>
            <year>2001</year>
            <month>Jun</month>
            <volume>113</volume>
            <issue>3</issue>
            <fpage>636</fpage>
            <page-range>636-41</page-range>
            <pub-id pub-id-type="pmid">11380449</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lijfering</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Brouwer</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Veeger</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Bank</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Coppens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Middeldorp</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hamuly&#x000e1;k</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Prins</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>B&#x000fc;ller</surname>
                <given-names>HR</given-names>
              </name>
              <name>
                <surname>van der Meer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives.</article-title>
            <source>Blood</source>
            <year>2009</year>
            <month>May</month>
            <day>21</day>
            <volume>113</volume>
            <issue>21</issue>
            <fpage>5314</fpage>
            <page-range>5314-22</page-range>
            <pub-id pub-id-type="pmid">19139080</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gladson</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Scharrer</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Hach</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Beck</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>The frequency of type I heterozygous protein S and protein C deficiency in 141 unrelated young patients with venous thrombosis.</article-title>
            <source>Thromb Haemost</source>
            <year>1988</year>
            <month>Feb</month>
            <day>25</day>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>18</fpage>
            <page-range>18-22</page-range>
            <pub-id pub-id-type="pmid">2966450</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lijfering</surname>
                <given-names>WM</given-names>
              </name>
              <name>
                <surname>Mulder</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>ten Kate</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Veeger</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Mulder</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>van der Meer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Clinical relevance of decreased free protein S levels: results from a retrospective family cohort study involving 1143 relatives.</article-title>
            <source>Blood</source>
            <year>2009</year>
            <month>Feb</month>
            <day>05</day>
            <volume>113</volume>
            <issue>6</issue>
            <fpage>1225</fpage>
            <page-range>1225-30</page-range>
            <pub-id pub-id-type="pmid">18945960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Adachi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Protein S and congenital protein S deficiency: the most frequent congenital thrombophilia in Japanese.</article-title>
            <source>Curr Drug Targets</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>6</volume>
            <issue>5</issue>
            <fpage>585</fpage>
            <page-range>585-92</page-range>
            <pub-id pub-id-type="pmid">16026279</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hackeng</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Rosing</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Protein S as cofactor for TFPI.</article-title>
            <source>Arterioscler Thromb Vasc Biol</source>
            <year>2009</year>
            <month>Dec</month>
            <volume>29</volume>
            <issue>12</issue>
            <fpage>2015</fpage>
            <page-range>2015-20</page-range>
            <pub-id pub-id-type="pmid">19661488</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heeb</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Rosing</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bakker</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Fernandez</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Tans</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Protein S binds to and inhibits factor Xa.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1994</year>
            <month>Mar</month>
            <day>29</day>
            <volume>91</volume>
            <issue>7</issue>
            <fpage>2728</fpage>
            <page-range>2728-32</page-range>
            <pub-id pub-id-type="pmid">8146182</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brouwer</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Veeger</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>van der Schaaf</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Kluin-Nelemans</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>van der Meer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Difference in absolute risk of venous and arterial thrombosis between familial protein S deficiency type I and type III. Results from a family cohort study to assess the clinical impact of a laboratory test-based classification.</article-title>
            <source>Br J Haematol</source>
            <year>2005</year>
            <month>Mar</month>
            <volume>128</volume>
            <issue>5</issue>
            <fpage>703</fpage>
            <page-range>703-10</page-range>
            <pub-id pub-id-type="pmid">15725093</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>ten Kate</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>van der Meer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Protein S deficiency: a clinical perspective.</article-title>
            <source>Haemophilia</source>
            <year>2008</year>
            <month>Nov</month>
            <volume>14</volume>
            <issue>6</issue>
            <fpage>1222</fpage>
            <page-range>1222-8</page-range>
            <pub-id pub-id-type="pmid">18479427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brouwer</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Veeger</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Kluin-Nelemans</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>van der Meer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The pathogenesis of venous thromboembolism: evidence for multiple interrelated causes.</article-title>
            <source>Ann Intern Med</source>
            <year>2006</year>
            <month>Dec</month>
            <day>05</day>
            <volume>145</volume>
            <issue>11</issue>
            <fpage>807</fpage>
            <page-range>807-15</page-range>
            <pub-id pub-id-type="pmid">17146065</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alvi</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Khan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Niazi</surname>
                <given-names>SK</given-names>
              </name>
              <name>
                <surname>Ghulam</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bibi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Acute mesenteric venous thrombosis: improved outcome with early diagnosis and prompt anticoagulation therapy.</article-title>
            <source>Int J Surg</source>
            <year>2009</year>
            <month>Jun</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>210</fpage>
            <page-range>210-3</page-range>
            <pub-id pub-id-type="pmid">19332155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Marlar</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Gausman</surname>
                <given-names>JN</given-names>
              </name>
            </person-group>
            <article-title>Protein S abnormalities: a diagnostic nightmare.</article-title>
            <source>Am J Hematol</source>
            <year>2011</year>
            <month>May</month>
            <volume>86</volume>
            <issue>5</issue>
            <fpage>418</fpage>
            <page-range>418-21</page-range>
            <pub-id pub-id-type="pmid">21523802</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hackeng</surname>
                <given-names>TM</given-names>
              </name>
              <name>
                <surname>Fern&#x000e1;ndez</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dawson</surname>
                <given-names>PE</given-names>
              </name>
              <name>
                <surname>Kent</surname>
                <given-names>SB</given-names>
              </name>
              <name>
                <surname>Griffin</surname>
                <given-names>JH</given-names>
              </name>
            </person-group>
            <article-title>Chemical synthesis and spontaneous folding of a multidomain protein: anticoagulant microprotein S.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>2000</year>
            <month>Dec</month>
            <day>19</day>
            <volume>97</volume>
            <issue>26</issue>
            <fpage>14074</fpage>
            <page-range>14074-8</page-range>
            <pub-id pub-id-type="pmid">11106381</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tripodi</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Asti</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chantarangkul</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Biguzzi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Mannucci</surname>
                <given-names>PM</given-names>
              </name>
            </person-group>
            <article-title>Interference of factor V Leiden on protein S activity: evaluation of a new prothrombin time-based assay.</article-title>
            <source>Blood Coagul Fibrinolysis</source>
            <year>2007</year>
            <month>Sep</month>
            <volume>18</volume>
            <issue>6</issue>
            <fpage>543</fpage>
            <page-range>543-6</page-range>
            <pub-id pub-id-type="pmid">17762529</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alshaikh</surname>
                <given-names>NA</given-names>
              </name>
              <name>
                <surname>Rosing</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Thomassen</surname>
                <given-names>MCLGD</given-names>
              </name>
              <name>
                <surname>Castoldi</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Simioni</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Hackeng</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>New functional assays to selectively quantify the activated protein C- and tissue factor pathway inhibitor-cofactor activities of protein S in plasma.</article-title>
            <source>J Thromb Haemost</source>
            <year>2017</year>
            <month>May</month>
            <volume>15</volume>
            <issue>5</issue>
            <fpage>950</fpage>
            <page-range>950-960</page-range>
            <pub-id pub-id-type="pmid">28211163</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Campello</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Spiezia</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Simion</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Tormene</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Camporese</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Dalla Valle</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Poretto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bulato</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Gavasso</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Radu</surname>
                <given-names>CM</given-names>
              </name>
              <name>
                <surname>Simioni</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Direct Oral Anticoagulants in Patients With Inherited Thrombophilia and Venous Thromboembolism: A Prospective Cohort Study.</article-title>
            <source>J Am Heart Assoc</source>
            <year>2020</year>
            <month>Dec</month>
            <volume>9</volume>
            <issue>23</issue>
            <fpage>e018917</fpage>
            <pub-id pub-id-type="pmid">33222589</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Folkeringa</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Brouwer</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Korteweg</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Veeger</surname>
                <given-names>NJ</given-names>
              </name>
              <name>
                <surname>Erwich</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Holm</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>van der Meer</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women.</article-title>
            <source>Br J Haematol</source>
            <year>2007</year>
            <month>Feb</month>
            <volume>136</volume>
            <issue>4</issue>
            <fpage>656</fpage>
            <page-range>656-61</page-range>
            <pub-id pub-id-type="pmid">17223916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yilmaz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gunaydin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Inherited risk factors in low-risk venous thromboembolism in patients under 45 years.</article-title>
            <source>Interact Cardiovasc Thorac Surg</source>
            <year>2015</year>
            <month>Jan</month>
            <volume>20</volume>
            <issue>1</issue>
            <fpage>21</fpage>
            <page-range>21-3</page-range>
            <pub-id pub-id-type="pmid">25326427</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Klostermeier</surname>
                <given-names>UC</given-names>
              </name>
              <name>
                <surname>Limperger</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Kenet</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kurnik</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Alhenc Gelas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Finckh</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Junker</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Zieger</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Kn&#x000f6;fler</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Holzhauer</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mesters</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Kr&#x000fc;mpel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Nowak-G&#x000f6;ttl</surname>
                <given-names>U</given-names>
              </name>
            </person-group>
            <article-title>Role of protein S deficiency in children with venous thromboembolism. An observational international cohort study.</article-title>
            <source>Thromb Haemost</source>
            <year>2015</year>
            <month>Feb</month>
            <volume>113</volume>
            <issue>2</issue>
            <fpage>426</fpage>
            <page-range>426-33</page-range>
            <pub-id pub-id-type="pmid">25272994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27882.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Monagle</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Cuello</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Augustine</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bonduel</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Brand&#x000e3;o</surname>
                <given-names>LR</given-names>
              </name>
              <name>
                <surname>Capman</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>AKC</given-names>
              </name>
              <name>
                <surname>Hanson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Male</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Meerpohl</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Newall</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>O'Brien</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Raffini</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>van Ommen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wiernikowski</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bhatt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Riva</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Roldan</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Schwab</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Mustafa</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Vesely</surname>
                <given-names>SK</given-names>
              </name>
            </person-group>
            <article-title>American Society of Hematology 2018 Guidelines for management of venous thromboembolism: treatment of pediatric venous thromboembolism.</article-title>
            <source>Blood Adv</source>
            <year>2018</year>
            <month>Nov</month>
            <day>27</day>
            <volume>2</volume>
            <issue>22</issue>
            <fpage>3292</fpage>
            <page-range>3292-3316</page-range>
            <pub-id pub-id-type="pmid">30482766</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
